世界卫生组织流感临床实践指南概要
本文为BMJ快速推荐对世界卫生组织2024年9月12日发布的流感指南的概要。指南针对季节性及人畜共患流感,提出29条推荐,涉及抗病毒药物和辅助治疗,并按疾病严重程度和进展风险分层。抗病毒治疗推荐包括重症在症状出现48小时内使用奥司他韦,以及高进展风险的非重症患者使用巴洛沙韦。
要点
- 重症流感建议症状出现48小时内使用奥司他韦。
- 非重症但高进展风险患者可使用巴洛沙韦治疗。
- 非重症流感强烈建议不使用抗生素。
核心结论
- WHO对季节性及人畜共患流感提出29条推荐,涉及抗病毒药物和辅助治疗。
- 抗病毒药物推荐按疾病严重程度和进展风险分层。
- 辅助治疗在非重症和重症流感中均不推荐常规使用。
研究设计与样本
- 指南由无利益冲突专家小组按照WHO手册方法制定。
- 证据来自4项随机对照试验的系统评价,总体证据确定性低至极低。
- 另有一项预后因素系统评价和决策分析模型支持诊断检测推荐。
主要发现
- 季节性流感重症患者,有条件推荐症状出现48小时内使用奥司他韦。
- 非重症但有高进展风险的患者,有条件推荐使用巴洛沙韦。
- 暴露于人畜共患流感者,有条件推荐使用巴洛沙韦、拉尼米韦、奥司他韦或扎那米韦预防。
- 暴露于季节性流感且风险极高者,有条件推荐预防用药。
- 非重症流感强烈推荐不使用抗生素;重症流感有条件推荐不使用皮质类固醇、大环内酯类、mTOR抑制剂、非甾体抗炎药和被动免疫治疗。
关键数值与推荐
- 推荐适用于季节性流感和人畜共患流感。
- 29条推荐中21条涉及抗病毒药物,6条涉及辅助治疗。
- 诊断检测策略在非重症和重症流感中均有推荐。
临床怎么用
- 临床决策应依据疾病严重程度和进展风险选择抗病毒药物。
- 对重症流感患者应尽早(48小时内)开始奥司他韦治疗。
- 避免对非重症流感患者常规使用抗生素。
- 对重症流感患者避免使用皮质类固醇等辅助治疗。
- 参照WHO推荐选择诊断检测策略以快速准确决定治疗。
局限性
- 抗病毒药物和辅助治疗获益与危害的证据确定性为低至极低。
- 指南未提供具体数值如阈值、剂量或P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABOUT THIS GUIDELINE: This BMJ Rapid Recommendation is a summary of a World Health Organization guideline published 12 September 2024. The full guideline is available in MAGICapp and in PDF on the WHO website. The WHO guideline is primarily for healthcare providers and takes a patient-centred perspective on benefits and harms. Other considerations include resource implications, acceptability, feasibility, equity, and human rights of relevance to healthcare systems. Recommendations were developed according to standards and methods for trustworthy guidelines by a panel of non-conflicted experts, as delineated in the WHO handbook (https://www.who.int/publications/i/item/9789241548960). CLINICAL QUESTIONS: What is the role of medications in treating non-severe and severe influenza including zoonotic disease (novel influenza A), and in preventing infection among contacts? Which diagnostic testing strategies best enable rapid and accurate treatment decisions? CONTEXT AND CURRENT PRACTICE: New randomised controlled trial (RCT) evidence, ongoing concerns about zoonotic disease, and the increasing availability of rapid diagnostic tests require updated guidance. RECOMMENDATIONS: apply to seasonal influenza and zoonotic influenza. There are 29 recommendations; 21 related to antiviral medications and six to adjunctive therapies to prevent and treat influenza. Recommendations are stratified by severity of disease and risk of disease progression. For seasonal influenza, WHO conditionally recommends treatment within 48 hours of symptom onset with oseltamivir for severe illness, and baloxavir for patients at high risk of progression from non-severe to severe illness. WHO also conditionally recommends prophylaxis (using baloxavir, laninimavir, oseltamivir, or zanamivir) for anyone exposed to zoonotic influenza, and for those exposed to seasonal influenza who are at extremely high risk. The panel issued recommendations against the use of adjunctive therapies in patients with non-severe influenza (strong recommendation against antibiotics) and severe influenza (conditional recommendation against corticosteroids, macrolides, mTOR inhibitors, non-steroidal anti-inflammatory drugs, and passive immune therapy). A recommendation is made for diagnostic testing strategies in non-severe and severe influenza disease. THE EVIDENCE: Four systematic reviews of RCTs provided low to very low certainty evidence on benefits and harms of antiviral medications and adjunctive therapies. A systematic review of prognostic factors provided baseline risk estimates and information on individual risk factors for disease progression. A decision analysis model informed recommendations for testing based on alternative potential diagnostic pathways.
引用
- Vandvik PO, Agarwal A, Rylance J, et al. Summary of WHO clinical practice guidelines for influenza. BMJ. 2026. PMID: 41760115. doi:10.1136/bmj-2025-087397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。